Central and peripheral dopamine transporter reduction in Parkinson's disease

Neurological Research

Volumn 31, Issue 7, 2009, Pages 687-691

  Buttarelli, Francesca R ^a   Capriotti, Gabriela ^a,b   Pellicano, Clelia ^a,b   Prosperi, Daniela ^b   Circella, Annapia ^a   Festa, Anna ^b   Giovannelli, Morena ^b   Tofani, Anna ^a,b   Pontieri, Francesco E ^a,b   Scopinaro, Francesco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine transporter; Immunocytochemistry; Parkinson's disease; Peripheral blood lymphocytes; Single photon emission computed tomography

Indexed keywords

CONTRAST MEDIUM; DOPAMINE TRANSPORTER; FLUOPANE I 123; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DENSITOMETRY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; MEASUREMENT; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN;

ADULT; AGED; CAUDATE NUCLEUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHOCYTES; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 68849106535     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X383259     Document Type: Article

References (26)

1. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184
2. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 2007; 22: 1229-1238
3. Amenta F, Ricci A, Tayebati SK, et al. The peripheral dopaminergic system: Morphological analysis, functional and clinical applications. Ital J Anat Embryol 2002; 107: 145-167
4. Caronti B, Tanda G, Colosimo C, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport 1999; 10: 2907-2910 (Pubitemid 29507751)
5. Caronti B, Antonini G, Calderaro C, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm 2001; 108: 803-807 (Pubitemid 32694403)
6. Pellicano C, Buttarelli FR, Circella A, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural Transm 2007; 114: 935-938 (Pubitemid 47013591)
7. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT-SPECT imaging: The [123I]-FP-CIT-Study Group. Mov Disord 2000; 15: 503-510 (Pubitemid 30333223)
8. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499 (Pubitemid 32995738)
9. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-140 (Pubitemid 27090931)
10. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of progression of Parkinson's disease. Exp Neurol 2003; 184 (Suppl. 1): S78-S89
11. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101 (Pubitemid 36764985)
12. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661 (Pubitemid 34289217)
13. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508
14. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 1997; 48: 969-977 (Pubitemid 27175624)
15. Uhl GR. Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 1998; 43: 555-560
16. Barroso N, Campos Y, Huertas R, et al. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson's disease. Clin Chem 1993; 39: 667-669 (Pubitemid 23118320)
17. Migliore L, Scarpato R, Coppede F, et al. Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int J Environ Health 2001; 204: 61-66 (Pubitemid 33031902)
18. Petrozzi L, Lucetti C, Gambaccini G, et al. Cytogenetic analysis of oxidative damage in lymphocytes of Parkinson's disease patients. Neurol Sci 2001; 22: 83-84 (Pubitemid 33622093)
19. Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis of leukocytes of Parkinson's disease patients. Neurology 2002; 58: 809-815 (Pubitemid 34663582)
20. Petrozzi L, Lucetti C, Scarpato R, et al. Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurol Sci 2002; 23: S97-S98 (Pubitemid 35355794)
21. Jimenez Del Rio M, Velz-Pardo C. 17 Beta-estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism. Implication for Parkinson's disease. Gen Pharmacol 2000; 35: 1-9
22. Blandini F, Mangiagalli A, Cosentino M, et al. Peripheral markers of apoptosis in Parkinson's disease: The effects of dopaminergic drugs. Ann NY Acad Sci 2003; 1010: 675-678 (Pubitemid 38265064)
23. Blandini F, Cosentino M, Mangiagalli A, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effects of dopaminergic treatment. J Neural Transm 2004; 111: 1017-1030 (Pubitemid 39037123)
24. Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006; 66: 529-534 (Pubitemid 43739882)
25. Kim S, Jeon BS, Heo C, et al. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J 2004; 18: 1615-1617 (Pubitemid 39561651)
26. Battisti C, Formichi P, Radi E, et al. Oxidative stress-induced apoptosis in PBLs of two patients with Parkinson's disease secondary to alpha-synuclein mutation. J Neurol Sci 2008; 267: 120-124 (Pubitemid 351248914)